Sickle cell disease (Q78965468)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

review article

1 reference

title

Sickle cell disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

Jason Fixler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

Lori Styles

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

Pediatric Clinics of North America

18 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

page(s)

1193-210, vi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

Frequency of Sickling Disorders in U.S. Blacks

18 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Sickling Rates of Human as Red Cells Infected in Vitro with Plasmodium falciparum Malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Pathophysiology of vaso-occlusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Pathogenesis and Treatment of Sickle Cell Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Septicemia caused by Salmonella infection: an overlooked complication of sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Recurrent Streptococcus pneumoniae sepsis in children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Patient-controlled analgesia for sickle-cell-related pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Patterns of mortality in sickle cell disease in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Fat embolism syndrome associated with asthma and sickle cell-beta(+)-thalassemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Pulse oximetry is a poor predictor of hypoxemia in stable children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Occlusion of Large Cerebral Vessels in Sickle-Cell Anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

The natural history of stroke in sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

The use of transcranial ultrasonography to predict stroke in sickle cell disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Stroke prevention trial in sickle cell anemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Human parvovirus infection in homozygous sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

FATAL FAT EMBOLISM SYNDROME IN A CHILD WITH UNDIAGNOSED HEMOGLOBIN S/Beta+ THALASSEMIA: A Complication of Acute Parvovirus B19 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Aplastic crisis due to extensive bone marrow necrosis and human parvovirus infection in sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Nature of concentrating defect in sickle-cell nephropathy. Microradioangiographic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Hematuria in sickie cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Neurologic events after partial exchange transfusion for priapism in sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Priapism in Children with Sickle Cell Anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Antiandrogens in the treatment of priapism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Sickle cell disease as a cause of osteonecrosis of the femoral head

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Bone disorders in sickle-cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Core decompression in avascular necrosis of the hip in sickle-cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Hip arthroplasty in patients with sickle-cell haemoglobinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Diagnosis and management of common bile duct stones in patients with sickle hemoglobinopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Blood rheology and proliferative retinopathy in homozygous sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Hemoglobin S-C disease revisited: clinical study of 106 adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Eye disease in sickling disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Health supervision for children with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Influence of sickle hemoglobinopathies on growth and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Current issues with blood transfusions in sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Techniques for blood administration in sickle cell patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Hydroxyurea therapy in children severely affected with sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Bone marrow transplantation for sickle cell disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Bone marrow transplantation for sickle cell disease: where do we go from here?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

Natural history and determinants of clinical severity of sickle cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

Patient-controlled analgesia in patients with sickle cell vaso-occlusive crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

Priapism as a complication of sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

Relief of sickle cell priapism by hydralazine. Report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

Sickle cell disease and silent avascular necrosis of the hip

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

Complications of sickle cell anemia in adults: guidelines for effective management

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

Secondary iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2802%2900089-5

7 January 2021

10.1016/S0031-3955(02)00089-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12580362%20AND%20SRC:MED&resulttype=core&format=json